Pfizer, BioNTech Covid-19 Vaccine

Google+ Pinterest LinkedIn Tumblr +

Two medical research companies, Pfizer and BioNTech SE in partnership have successfully manufactured and carried out a successful clinical trial for COVID 19 vaccine. Their statistics show the vaccine is 90% effective in preventing COVID-19. This comes as a relief to the world as nations deal with the pandemic that has killed thousands of people and adversely affected the overall world’s economy.

Pfizer’s chairman, Albert Bourla was elated in one of the interviews as he announced the significant breakthrough in the fight against the global pandemic. He pointed out that the vaccine’s development success has happened when the world needed it most; the hospital struggling with over-capacity due to huge numbers of COVID-19 new infections being recorded recently, and the world looking at possibilities of opening the struggling economies fully since the worldwide lockdowns from March.

Pfizer explained that they will seek emergency use authorization of the coronavirus vaccine from the U.S government with projected 44,000 participants in the study. The vaccination exercises will be limited with only citizens aged between 16 to 85 years being allowed.

However, even with the new vaccine success, there are still unanswered health concerns. For instance, how long will the vaccine protection last before a need for another vaccination?

The U.S alone requires around 660 million doses for the entire U.S. population which should be attained by mid-2021. Pfizer can’t meet such demand within a short time, although they are projecting to make 1.3 billion doses by the end of 2021 to a percentage of demand from other regions too. So far, the company is in partnership valued at $1.95 billion with the US government. They are expected to deliver about 100 million COVID-19 doses. The vaccine will be offered for free to all US citizens within the given bracket.

Owing to the huge demand for Coronavirus vaccine from across the world, other leading drug-making companies such as Johnson & Johnson Inc, Moderna Inc, and AstraZeneca PLC have not been left behind. They have signed multibillion-dollar vaccines supply deals with wealthy countries since their vaccines’ clinical trial results are quite promising.



About Author

Anthony Kiratu is the Founder of Finsolutions. He is a financial analyst with over 5 years experience in research, investment advisory, valuation and financial modelling. Anthony is a member of the Institute of Certified Investment and Financial Analysts and Institute of Certified Public Accountants of Kenya. He is passionate about development of African Capital Markets through training of investors and dissemination of information for sound financial and investment decision making process. He is also a part-time lecturer in the Certified Investment and Financial Analyst course in the subjects of International Finance, Portfolio Management, Equity Investment Analysis, and Fixed Income Securities. Email: Contact: +254 780216631

Leave A Reply